Galectin Historical Valuation

GALT Stock  USD 1.04  0.96  48.00%   
Some fundamental drivers such as market cap or Galectin Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Galectin Therapeutics valuation indicators such as Enterprise Value of 104.5 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Galectin Therapeutics's future value.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

About Galectin Valuation Data Analysis

Valuation is the financial process of determining what Galectin Therapeutics is worth. Galectin Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Galectin Therapeutics valuation ratios help investors to determine whether Galectin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Galectin with respect to the benefits of owning Galectin Therapeutics security.

Galectin Therapeutics Valuation Data Chart

Market Cap is likely to gain to about 114.5 M in 2024. Enterprise Value is likely to gain to about 104.5 M in 2024

Working Capital

The difference between a company's current assets and current liabilities, indicating the liquidity and operational efficiency of the business.

Enterprise Value

Enterprise Value (or EV) is usually referred to as Galectin Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Galectin Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Galectin Therapeutics value than its market capitalization because it takes into account all of Galectin Therapeutics existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.